SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

Press Release:

SynCardia Total Artificial Heart Featured in 12 ISHLT Abstracts

The April 15-18 annual meeting of the International Society of Heart and Lung Transplantation will include abstracts on the SynCardia Total Artificial Heart, the Freedom portable driver and the 3D virtual implantation of the 50cc SynCardia Heart.

Two multi-center abstracts: Postmarket Surveillance Study (PSS) vs. Pre-Market Approval (PMA) and results for the Freedom® portable driver. Two multi-center abstracts: Postmarket Surveillance Study (PSS) vs. Pre-Market Approval (PMA) and results for the Freedom® portable driver. TUCSON, Ariz. TUCSON, Ariz. – Apr. 7, 2015 – Twelve abstracts and posters on the SynCardia temporary Total Artificial Heart will be part of the 35th Annual Meeting and Scientific Sessions by The International Society for Heart & Lung Transplantation (ISHLT).

The annual international gathering will be April 15-18, 2015, in Nice, France.

“With more than 1,400 SynCardia Total Artificial Heart implants worldwide, surgeons and heart failure cardiologists have researched and provided abstracts on the SynCardia Heart,” says Michael P. Garippa, CEO and President of SynCardia Systems, Inc. “These abstracts provide data documenting the value of SynCardia’s Total Artificial Heart technology.”

Key SynCardia Heart presentations at the meeting include multiple-center abstracts:

Here is the schedule of other key presentations regarding the SynCardia Total Artificial Heart:

 

###

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.

More than 1,400 implants of the SynCardia Total Artificial Heart account for over 400 patient years of life on the device. Since January 2010 more than 600 SynCardia Hearts have been implanted.

The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant Sept. 11, 2011.

SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home and in their communities. The wearable Freedom driver has been used by more than 200 patients, accounting for over 130 years of support.

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas